The tumor microenvironment: Focus on myeloma

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 1, 2003, Pages 11-19

  Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cell adhesion; Drug resistance; Fibronectin; Myeloma

Indexed keywords

AG 957; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; BETA1 INTEGRIN; BORTEZOMIB; CD40 ANTIGEN; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DRUG METABOLIZING ENZYME; ETOPOSIDE; FAS ANTIGEN; IMATINIB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; M PROTEIN; MELPHALAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOSIDE ANALOG; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; SYNDECAN 1; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VINCRISTINE;

ADAPTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL INTERACTION; CELL MEMBRANE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TOLERANCE; DRUG TRANSPORT; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; ION TRANSPORT; MEMBRANE BINDING; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN SYNTHESIS; REVIEW; STROMA; STROMA CELL; TUMOR CELL; UPREGULATION;

EID: 0038528630     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00077-X     Document Type: Review

References (71)

1. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 1999; 59(5): 1021-1028.
2. Grogan TM, Spier CM, Salmon SE, et al. P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81(2): 490-495.
3. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999; 26(5 Suppl. 13): 23-27.
4. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7(4): 415-424.
5. Sonneveld P, Marie JP, Huisman C, et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10(11): 1741-1750.
6. Abbaszadegan MR, Foley NE, Gleason-Guzman MC, Dalton WS. Resistance to the chemosensitizer verapamil in a multidrug-resistant (MDR) human multiple myeloma cell line. Int J Cancer 1996; 66(4): 506-514.
7. Linsenmeyer ME, Jefferson S, Wolf M, et al. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65(3): 471-475.
8. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 273(36): 27845-27850.
9. Durand RE, Sutherland RM. Effects of intercellular contact on repair of radiation damage. Exp Cell Res 1972; 71(1): 75-80.
10. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5(6): 662-668.
11. Hoyt DG, Rusnak JM, Mannix RJ, et al. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 1996; 56(18): 4146-4149.
12. Oloumi A, MacPhail SH, Johnston PJ, et al. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 2000; 60(20): 5747-5753.
13. St Croix B, Florenes VA, Rak JW, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996; 2(11): 1204-1210.
14. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267(5199): 891-893.
15. Wartenberg M, Donmez F, Ling FC, et al. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J 2001; 15(6): 995-1005.
16. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247(4949 Pt 1): 1457-1461.
17. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997; 57(2): 2388-2393.
18. Meredith Jr JE, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell Biol 1997; 7: 146-151.
19. Vizirianakis IS, Chen YQ, Kantak SS, et al. Dominant-negative E-cadherin alters adhesion and reverses contact inhibition of growth in breast carcinoma cells. Int J Oncol 2002; 21(1): 135-144.
20. Meredith Jr JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4(9): 953-961.
21. Assoian RK. Anchorage-dependent cell cycle progression. J Cell Biol 1997; 136(1): 1-4.
22. St Croix B, Sheehan C, Rak JW, et al. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998; 142(2): 557-571.
23. Rodeck U, Jost M, DuHadaway J, et al. Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc Natl Acad Sci USA 1997; 94(10): 5067-5072.
24. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and upregulates Bcl-2 expression. Proc Natl Acad Sci USA 1995; 92(13): 6161-6165.
25. Folkman J, Moscona A. Role of cell shape in growth control. Nature 1978; 273(5661): 345-349.
26. Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91(7): 2387-2396.
27. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93(5): 1658-1667.
28. Higashimoto I, Chihara J, Kakazu T, et al. Regulation of eosinophil cell death by adhesion to fibronectin. Int Arch Allergy Immunol 1996; 111(Suppl. 1): 66-69.
29. Zaitseva MB, Mojcik CF, Salomon DR, et al. Co-ligation of alpha4beta1 integrin and TCR rescues human thymocytes from steroid-induced apoptosis. Int Immunol 1998; 10(10): 1551-1561.
30. de la Fuente MT, Casanova B, Garcia-Gila M, et al. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999; 13(2): 266-274.
31. Meyer N, Duensing S, Anastassiou G, et al. Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine. Anticancer Res 1999; 19(2C): 1509-1512.
32. Hikawa T, Mori T, Abe T, Hori S. The ability in adhesion and invasion of drug-resistant human glioma cells. J Exp Clin Cancer Res 2000; 19(3): 357-362.
33. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol 2001; 152(3): 633-643.
34. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38(1-2): 71-81.
35. Hazlehurst LA, Damiano JS, Buyuksal I, et al. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19(38): 4319-4327.
36. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001; 15(8): 1232-1239.
37. Hazlehurst LA, Valkov N, Wisner L, et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98(6): 1897-1903.
38. Anderson KC. Plasma cell tumors. In: Bast Jr RC, Kufe DW, Pollack RE, Weichselbaum RR, Holland JR, Frei E, Gansler TS (eds.), Cancer medicine. 5th ed. BC Decker: Hamilton, Ont., 2001; 2066-2085.
39. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol 2000; 12(6): 557-563.
40. Kawano MM, Huang N, Tanaka H, et al. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br J Haematol 1991; 79(4): 583-588.
41. Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82(12): 3712-3720.
42. Gimble JM, Pietrangeli C, Henley A, et al. Characterization of murine bone marrow and spleen-derived stromal cells: analysis of leukocyte marker and growth factor mRNA transcript levels. Blood 1989; 74(1): 303-311.
43. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20(33): 4519-4527.
44. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95(8): 2630-2636.
45. Urashima M, Chauhan D, Uchiyama H, et al. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85(7): 1903-1912.
46. Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93(1): 300-305.
47. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355(9200): 248-250.
48. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84(9): 3063-3070.
49. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89(1): 227-234.
50. Thomas X, Anglaret B, Magaud JP, et al. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma 1998; 32(1-2): 107-119.
51. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49(1): 11-19.
52. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5(8): 2048-2058.
53. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168(5): 2544-2553.
54. Nagata S, Golstein P. The Fas death factor. Science 1995; 267(5203): 1449-1456.
55. Nagata S. Apoptosis by death factor. Cell 1997; 88(3): 355-365.
56. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14(22): 5579-5588.
57. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268(15): 10932-10937.
58. Wang MW, Consoli U, Lane CM, et al. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 1998; 9(2): 105-112.
59. Koopman G, Keehnen RM, Lindhout E, et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994; 152(8): 3760-3767.
60. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999; 5(2): 425-430.
61. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57(21): 4956-4964.
62. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95(1): 301-308.
63. Landowski TH, Shain KH, Oshiro MM, et al. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood 1999; 94(1): 265-274.
64. Shain KH, Landowski TH, Buyuksal I, et al. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000; 14(5): 830-840.
65. Landowski TH, Qu N, Buyuksal I, et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90(11): 4266-4270.
66. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10(1): 105-115.
67. Read MA, Neish AS, Luscinskas FW, et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2(5): 493-506.
68. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61(7): 3071-3076.
69. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999; 107(4): 825-834.
70. Robledo MM, Sanz-Rodriguez F, Hidalgo A, Teixido J. Differential use of very late antigen-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to transforming growth factor-beta1-treated bone marrow stroma. J Biol Chem 1998; 273(20): 12056-12060.
71. Ridley RC, Xiao H, Hata H, et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81(3): 767-774.